The earnings call highlighted Myriad Genetics' positive revenue growth, strategic focus on high-growth market segments, and improved profitability metrics despite challenges such as the UnitedHealthcare policy impact on GeneSight and a temporary decline in prenatal volumes. The company is actively addressing these challenges and securing new strategic partnerships.

Company Guidance

During the Myriad Genetics Second Quarter 2025 Financial Earnings Conference Call, the company reported a revenue of $213 million, marking a 5% year-over-year increase when adjusting for UnitedHealthcare's decision on GeneSight and the divestiture of the European EndoPredict business. Myriad's strong performance was driven by a 2% year-over-year growth in average revenue per test, supported by robust execution in pricing improvement initiatives. The company highlighted a 14% increase in MyRisk HCT testing volume within oncology and a 5% growth in GeneSight volume. However, prenatal product volumes, including Prequel and Foresight, declined by 7% due to challenges with a new order management system, which has since been resolved. The adjusted gross margin improved to 71.5%, a 140 basis point increase from the previous year, and adjusted EBITDA reached $14.5 million, reflecting a 24% growth. Myriad also secured a $200 million term loan from OrbiMed to support its growth journey. The company raised its 2025 guidance, projecting full-year revenues between $818 million and $828 million and targeting high single-digit to low double-digit revenue growth over the next five years by focusing on the Cancer Care Continuum.

Revenue Growth and Profitability

Myriad Genetics reported a revenue increase of 5% year-over-year, excluding impacts from UnitedHealthcare's decision on GeneSight and divested European EndoPredict business. The company also achieved a strong adjusted gross margin of 71.5%, a 140 basis points increase from the previous year, and reported an adjusted EBITDA of $14.5 million, representing a 24% growth over last year.

Hereditary Cancer Testing (HCT) Growth

The company reported strong volume growth for MyRisk HCT in oncology at 14% over the year-ago quarter. There was also a modest but improving 3% volume growth in the unaffected population.

Prenatal Products and Future Launches

Despite a decline in volume due to order management system issues, prenatal revenue grew by 7% year-over-year. The company expects improving trends in prenatal volume growth starting in Q3 after fixing the ordering system issue.

Strategic Focus on Cancer Care Continuum

Myriad Genetics announced a strategic focus on the Cancer Care Continuum, aiming to drive accelerated growth and profitability by expanding their testing portfolio and leveraging strategic partnerships.

Securing $200 Million Term Loan

Myriad secured a $200 million term loan from OrbiMed, providing the company with liquidity and flexibility to support growth.

Myriad Genetics (MYGN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

MYGN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 04, 2025	2025 (Q3)	-0.01 / -	0.06	―	―	―
Aug 05, 2025	2025 (Q2)	>-0.01 / 0.05	0.05	0.00% (0.00)
May 06, 2025	2025 (Q1)	-0.06 / -0.03	-0.01	-200.00% (-0.02)
Feb 24, 2025	2024 (Q4)	0.03 / 0.03	0.04	-25.00% (-0.01)
Nov 07, 2024	2024 (Q3)	0.02 / 0.06	-0.03	300.00% (+0.09)
Aug 06, 2024	2024 (Q2)	-0.01 / 0.05	-0.08	162.50% (+0.13)
May 07, 2024	2024 (Q1)	-0.10 / -0.01	-0.21	95.24% (+0.20)
Feb 27, 2024	2023 (Q4)	0.01 / 0.04	-0.12	133.33% (+0.16)
Nov 06, 2023	2023 (Q3)	-0.08 / -0.03	-0.19	84.21% (+0.16)
Aug 03, 2023	2023 (Q2)	-0.08 / -0.08	0.04	-300.00% (-0.12)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

MYGN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$3.87	$5.67	+46.51%
May 06, 2025	$7.27	$4.27	-41.27%
Feb 24, 2025	$13.78	$11.74	-14.80%
Nov 07, 2024	$17.67	$17.41	-1.47%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Myriad Genetics (MYGN) report earnings?

Myriad Genetics (MYGN) is schdueled to report earning on Nov 04, 2025, TBA (Confirmed).

What is Myriad Genetics (MYGN) earnings time?

Myriad Genetics (MYGN) earnings time is at Nov 04, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is MYGN EPS forecast?

MYGN EPS forecast for the fiscal quarter 2025 (Q3) is -0.01.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing